This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
STERIS (STE) Gains From New Offerings, Macro Issues Ail
by Zacks Equity Research
STERIS' (STE) AST successfully offers a wide range of sterilization modalities through a worldwide network of more than 50 contract sterilization and laboratory facilities.
Steris (STE) Up 2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Unlocking Steris (STE) International Revenues: Trends, Surprises, and Prospects
by Zacks Equity Research
Explore how Steris' (STE) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
STERIS (STE) Q4 Earnings Match Estimates, Margins Contract
by Zacks Equity Research
STERIS' (STE) fourth-quarter performance in AST is dented by a decline in capital equipment revenues. The contraction of margins is concerning.
Steris (STE) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Steris (STE) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Steris (STE) Matches Q4 Earnings Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 0% and 3.07%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Shockwave Medical (SWAV) Earnings Expected to Grow: What to Know Ahead of Q1 Release
by Zacks Equity Research
Shockwave Medical (SWAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exploring Analyst Estimates for Steris (STE) Q4 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Get a deeper insight into the potential performance of Steris (STE) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
The Zacks Analyst Blog Highlights Micron Technology, Anheuser-Busch, Duke Energy, ON Semiconductor and STERIS
by Zacks Equity Research
Micron Technology, Anheuser-Busch, Duke Energy, ON Semiconductor and STERIS are included in this Analyst Blog.
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sight Sciences (SGHT) delivered earnings and revenue surprises of -13.79% and 5.06%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Top Stock Reports for Micron Technology, Anheuser-Busch & Duke Energy
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Micron Technology, Inc. (MU), Anheuser-Busch InBev SA/NV (BUD) and Duke Energy Corporation (DUK).
Here's Why You Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
STERIS' (STE) strong prospects in the healthcare and pharmaceutical industries bode well for investors.
Should You Buy STERIS (STE) Stock Ahead of Q4 Earnings?
by Zacks Equity Research
STERIS (STE) is expected to have witnessed the normalization of the Healthcare backlog, as the company is currently able to ship at a faster pace than the receipt of new orders.
Zacks Industry Outlook Highlights Edwards Lifesciences, DexCom and STERIS
by Zacks Equity Research
Edwards Lifesciences, DexCom and STERIS have been highlighted in this Industry Outlook article.
3 Medical Instruments Stocks to Buy Amid Improving Industry Trends
by Urmimala Biswas
The Zacks Medical - Instruments industry is expected to gain from the rising adoption of smart healthcare options, including genAI. However, supply issues and staffing shortages continue to disrupt growth. EW, DXCM and STE appear well-poised to brave the challenges.
Here's Why Steris (STE) is Poised for a Turnaround After Losing -9.06% in 4 Weeks
by Zacks Equity Research
The heavy selling pressure might have exhausted for Steris (STE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Here's Why Investors Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
Investors are optimistic about STERIS (STE) on strong Healthcare business performance and raised 2024 guidance.
Globus Medical (GMED) Down 5.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Steris (STE) Up 5.8% Since Last Earnings Report?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Investors Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
Investors are optimistic about STERIS (STE) on continuous recovery of healthcare procedures and upbeat 2024 guidance.
Why Steris (STE) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Steris (STE) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
STERIS (STE) Q3 Earnings Top Estimates, Fiscal '24 Sales View Up
by Zacks Equity Research
STERIS' (STE) fiscal 2024 third-quarter results demonstrate the remarkable performance of the Healthcare segment.
Compared to Estimates, Steris (STE) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Steris (STE) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Steris (STE) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 2.30% and 4.22%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?